skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Opaganib (Code C98278)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Opaganib

Definition: An orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, opaganib competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2. SK2 and its isoenzyme SK1 are overexpressed in numerous cancer cell types.

Display Name: Opaganib

Label: Opaganib

NCI Thesaurus Code: C98278 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2933331  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
4-Pyridinylmethyl-3-(4-chlorophenyl) Adamantane Carboxamide
ABC 294640
SK2 inhibitor ABC294640
Tricyclo(,7)decane-1-carboxamide, 3-(4-Chlorophenyl)-N-(4-pyridinylmethyl)-

External Source Codes: 
CAS Registry Number 915385-81-8 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 712053
PDQ Open Trial Search ID 712053 (check for NCI PDQ open clinical trial info)
UMLS CUI C2933331

Other Properties:
     Name Value (qualifiers indented underneath)
code C98278
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom